Published in N Engl J Med on May 10, 2007
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) | NCT00092534
Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers (Girasol) | NCT00925288
Acceptance of Human Papillomavirus Vaccination in Postpartum Women (HPV Acceptance) | NCT00730704
Evaluation of Long Term Immunity Following HPV Vaccination | NCT02276521
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ (2007) 3.77
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Rethinking global access to vaccines. BMJ (2008) 3.60
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol (2009) 2.46
Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med (2010) 2.33
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis (2010) 2.03
Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst (2013) 1.99
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer (2011) 1.96
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol (2010) 1.94
Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ (2007) 1.86
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med (2010) 1.81
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. Am J Public Health (2012) 1.76
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ (2007) 1.72
HPV vaccine decision making in pediatric primary care: a semi-structured interview study. BMC Pediatr (2011) 1.72
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med (2013) 1.64
HPV vaccination--more answers, more questions. N Engl J Med (2007) 1.64
The differential diagnosis and interdisciplinary treatment of anal carcinoma. Dtsch Arztebl Int (2015) 1.62
Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol (2009) 1.60
Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol (2008) 1.59
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis (2014) 1.58
Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics (2010) 1.57
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health (2010) 1.53
Predicting human papillomavirus vaccine uptake in young adult women: comparing the health belief model and theory of planned behavior. Ann Behav Med (2012) 1.53
Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Womens Health (2010) 1.51
Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS One (2014) 1.50
Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48
Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer (2007) 1.48
A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer (2012) 1.47
Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst (2010) 1.46
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. J Natl Cancer Inst (2015) 1.45
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010. Cancer (2012) 1.41
Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Annu Rev Public Health (2010) 1.39
Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine (2010) 1.38
STI management and control in North America IUSTI region. Sex Transm Infect (2011) 1.38
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One (2010) 1.37
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37
Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol (2008) 1.35
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis (2011) 1.34
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med (2009) 1.29
The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int (2014) 1.26
A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer (2014) 1.26
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med (2011) 1.23
Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. Semin Hematol (2012) 1.22
Perspectives on decision making about human papillomavirus vaccination among 11- to 12-year-old girls and their mothers. Clin Pediatr (Phila) (2012) 1.21
Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus vaccine. Saudi Med J (2014) 1.20
Genital HPV infection and related lesions in men. Prev Med (2011) 1.19
Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med (2011) 1.18
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol (2009) 1.16
Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health (2012) 1.16
Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis (2011) 1.15
Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med (2008) 1.15
The paediatric story of human papillomavirus (Review). Oncol Lett (2014) 1.15
The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis (2009) 1.14
Is human papillomavirus vaccination likely to be a useful strategy in India? South Asian J Cancer (2013) 1.14
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
Use of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey. Cancer (2011) 1.12
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics (2012) 1.10
Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med (2010) 1.09
Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med (2011) 1.09